By Dr Charlotte Rose Lemech

Other

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, Data from Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance, http://dx.doi.org/10.1158/1078-0432.c.8715322

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, Supplementary Data 1 from Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance, http://dx.doi.org/10.1158/1078-0432.33775921

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Data from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.c.8600817

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014559

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014556

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014553

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014550

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014547

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014544

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014541

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014538

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014535

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014532

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Castañón Álvarez E; Yang JC-H; Ascierto PA; Provencio Pulla M; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im S-A, 2026, Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody, http://dx.doi.org/10.1158/1078-0432.33014529

Back to profile page